What is the therapeutic effect of Rimegepant orally disintegrating tablets?

Rimegepant orally disintegrating tablets (Rimegepant) is a new type of drug mainly used to treat migraine . Its mechanism of action is to block the binding of calcitonin gene-related peptide (CGRP) to its receptors, thereby reducing migraine symptoms and preventing attacks. CGRP is a chemical messenger that plays an important role in migraine attacks, so by intervening in this mechanism, remagepam can help relieve patients' symptoms.

Multiple clinical studies have confirmed the efficacy of remijipan. Three major studies, involving approximately 3,500 adults, showed that remagepam was significantly better than placebo (dummy therapy) in treating migraines. Subjects who experienced a moderate to severe migraine rated their pain level using a 4-point Likert scale (0 = no pain, 1 = mild, 2 = moderate, 3 = severe) within two hours of treatment. The results showed that an average of 20% of patients who took remagepan had their headaches disappear after two hours, while only about 12% of patients who took a placebo had their headaches disappear. This result shows that remagepan has a significant effect in relieving migraine headaches.

In addition, remijipan also shows good efficacy in treating other migraine-related symptoms, such as photophobia, sound sensitivity and nausea. The results of the study showed that about 36% of the patients who received remagepan did not experience the above symptoms two hours later, while only about 27% of the patients who took the placebo did not experience these symptoms. This further demonstrates the effectiveness of remagepam in the comprehensive treatment of migraine.

Additionally, Remedipam has been shown to reduce the frequency of monthly migraine attacks in patients. One study involving 747 adults showed that these patients had between four and 18 migraine attacks per month. In the 12-week trial, patients were divided into groups receiving remiagepam or placebo. The results showed that during the last 4 weeks of the study, patients receiving remagepam experienced an average reduction of 4.3 migraine days per month, while the placebo group experienced a reduction of 3.5 days. This suggests that remagepan not only provides rapid relief of acute migraine attacks but is also effective in preventing future attacks.

Reference materials:https://en.wikipedia.org/wiki/Rimegepant